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ABSTRACT 
Nonalcoholic fatty liver disease (NAFLD) has, although it is a very common disorder, 
only relatively recently gained broader interest among physicians and scientists. Fatty 
liver has been documented in up to 10 to 15 percent of normal individuals and 70 to 
80 percent of obese individuals. Although the pathophysiology of NAFLD is still 
subject to intensive research, several players and mechanisms have been suggested 
based on the substantial evidence. Excessive hepatocyte triglyceride accumulation 
resulting from insulin resistance is the first step in the proposed ‘two hit’ model of 
the pathogenesis of NAFLD. Oxidative stress resulting from mitochondrial fatty acids 
oxidation, NF-κB-dependent inflammatory cytokine expression and adipocytokines 
are all considered to be the potential factors causing second hits which lead to 
hepatocyte injury, inflammation and fibrosis. Although it was initially believed that 
NAFLD is a completely benign disorder, histologic follow-up studies have showed that 
fibrosis progression occurs in about a third of patients. Small number of patients with 
NAFLD eventually ends up with end-stage liver disease and even hepatocellular 
carcinoma. Although liver biopsy is currently the only way to confirm the NAFLD 
diagnosis and distinguish between fatty liver alone and NASH, no guidelines or firm 
recommendations can still be made as for when and in whom it is necessary. 
Increased physical activity, gradual weight reduction and in selected cases bariatric 
surgery remain the mainstay of NAFLD therapy. Studies with pharmacologic agents 
are showing promising results, but available data are still insufficient to make specific 
recommendations; their use therefore remains highly individual. 
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INTRODUCTION AND EPIDEMIOLOGY  
 
Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized cause of 
liver-related morbidity and mortality. It represents a spectrum of hepatic disorders 
characterized by macrovesicular steatosis that occur in the absence of alcohol 
consumption in amounts generally considered to be harmful to the liver (less than 40 
g of ethanol per week). That spectrum ranges from simple hepatic steatosis without 
concomitant inflammation or fibrosis to hepatic steatosis with a necroinflammatory 
component that may or may not have associated fibrosis (non-alcoholic 
steatohepatitis - NASH) and can progress to cirrhosis.  
Although the association of macrovesicular steatosis of the liver with 
inflammatory changes and fibrosis in obese subjects has been known for several 
decades, it was largely ignored as a clinical entity. The term "nonalcoholic 
steatohepatitis" was first introduced in 1980 by Ludwig et al. and is used to describe 
the distinct clinical entity in which patients have liver biopsy findings indistinguishable 
from alcoholic hepatitis but lack a history of significant alcohol consumption [1].  
The true incidence and prevalence of NAFLD are unknown. Population-based 
studies most often use imaging modalities or serum alanine aminotransferase levels 
to diagnose NAFLD [2-4]. These studies are limited by inability to make a definitive 
diagnosis of NAFLD or to distinguish between NAFLD and NASH, which requires liver 
biopsy. Studies that have used strict definitions for diagnosis including biopsies were 
most often based on specific subsets of population (e.g. diabetics, obese individuals, 
in-hospital patients) and they cannot be applied to general population [5-7]. Despite 
the limitations of the published data, several facts are consistently present. Fatty 
liver and NASH have been reported in all age groups, including children [4, 8]. The 
prevalence increases with increasing body weight [6,9]. Fatty liver has been 
documented in up to 10 to 15 percent of normal individuals and 70 to 80 percent of 
obese individuals. Correspondingly, about 3 percent of normal individuals and 15 to 
20 percent of morbidly obese subjects (BMI >35 kg/m2) have steatohepatitis [6, 10]. 
These findings are of particular concern given the increasing prevalence of obesity in 
virtually all age groups. The highest prevalence is in those between 40 and 60 years 
of age [7, 11, 12]. Although earlier studies found higher prevalence of NASH in women 
(65 to 85 percent of all patients), more recent studies have shown that NASH occurs 
with equal frequency in both sexes [1, 7, 11, 13]. In the United States, there appear to 
be ethnic differences in the prevalence of NASH. A higher prevalence of hepatic 
steatosis was found in Hispanics (45 percent) compared with Caucasians (33 
percent) or Afro-Americans (24 percent) [14]. 
There is increasing evidence that NAFLD represents the hepatic component of 
a metabolic syndrome characterized by obesity, hyperinsulinemia, peripheral insulin 
resistance, diabetes, hypertriglyceridemia, and hypertension. Type 2 diabetes 
mellitus is a major component of the metabolic syndrome and is associated with both 
obesity and NASH [1, 12, 13, 15]. It has been described in 34 to 75 percent of patients 
with NASH. Diabetes is not only associated with NAFLD but also may be a risk factor 
for development of progressive liver fibrosis [16]. Obesity has been reported in 70 to 
100 percent of cases of NASH, and most patients are 10 to 40 percent above ideal 
body weight [1, 12, 13, 15]. Numerous reports have documented resolution of fatty liver 
following gradual weight loss. Subjects with abdominal obesity are more prone to 
developing diabetes and hypertension as well as fatty liver. Hyperlipidemia 
(hypertriglyceridemia and/or hypercholesterolemia), which is frequently associated 
with both obesity and type 2 diabetes, has been reported in 20 to 80 percent of 
patients with NASH [1, 12, 13, 15]. 
In addition, NAFLD has been associated with several rare disorders of lipid 
metabolism and insulin resistance (e.g. abetalipoproteinemia, lipoatrophic diabetes, 
Mauriac and Weber-Christian syndrome), as well as with total parenteral nutrition, 
acute starvation, intravenous glucose therapy, abdominal surgery (e.g. extensive 
small bowel resection, biliopancreatic diversion, and jejunal bypass), use of several 
drugs (e.g. amiodarone, tamoxifen, glucocorticoids, and synthetic estrogens) and 
several types of chemicals (e.g. organic solvents and dimethylformamide) [17-21, 22-26, 
27-31]. The incidence, mechanism, and natural history of these forms of NAFLD are 
unknown.  
Several studies reported that many patients with NASH have biochemical 
evidence of iron overload, with elevation of transferrin saturation and serum ferritin 
level. Patients with NASH were found to be homozygous or heterozygous for the 
Cys282Tyr mutation in HFE gene in significantly higher percent than the general 
population. However, the hepatic iron index was <1.9 in all patients. The presence of 
iron overload has been reported to be associated with increased hepatic fibrosis, but 
this finding was not confirmed by other reports. The significance of the HFE 
mutations in NASH remains to be fully established [32-36]. 
 
HOW DOES IT DEVELOP? - NAFLD PATHOGENESIS  
 
A large body of evidence clearly indicates that NAFLD is principally associated with 
the metabolic syndrome. Therefore, two types of NAFLD can be recognized: primary 
NAFLD (associated with metabolic syndrome) and secondary NAFLD (associated with 
other specific metabolic or iatrogenic conditions distinct from the metabolic 
syndrome). 
Pathophysiology of primary NAFLD still hasn’t been completely clarified. The so 
called 'two hit' model of the pathogenesis of NAFLD has been proposed since 1998 
[37]. Liver fat accumulation is the suggested ‘first hit’ or the first step. It is a 
consequence of excessive triglyceride accumulation caused by discrepancy between 
influx and synthesis of hepatic lipids on one side and their β-oxidation and export on 
the other (Figure 1) [38]. This imbalance occurs with all of the previously mentioned 
potential etiologic factors. The steatotic liver subsequently becomes vulnerable to 
presumed 'second hits' leading to hepatocyte injury, inflammation and fibrosis. The 
most widely supported theory implicates insulin resistance as the key mechanism in 
primary NAFLD, leading to hepatic steatosis, and perhaps also to steatohepatitis. The 
presumed factors initiating second hits are oxidative stress and subsequent lipid 
peroxidation, proinflammatory cytokines (principally TNF-α), and hormones derived 
from adipose tissue (adipocytokines). (Figure 1.) 
Obesity, type 2 diabetes, hyperlipidemia and other conditions associated with insulin 
resistance are generally present in patients with NAFLD. Insulin resistance has also 
been observed in patients with NAFLD who are not obese and in those with normal 
glucose tolerance [39-41]. The molecular mechanism leading to insulin resistance is 
complex and hasn’t been elucidated completely. Several molecules (tumor necrosis 
factor alpha, PC-1 membrane glycoprotein, leptin, and fatty acids) appear to interfere 
with insulin signalling pathway [42]. Alterations in lipid metabolism associated with 
insulin resistance result from the interaction between the effects of insulin resistance 
located primarily in muscles and adipose tissue and impact of the compensatory 
hyperinsulinemia on tissues that remain insulin sensitive. These alterations include 
enhanced peripheral lipolysis, increased hepatic uptake of FFAs and increased 
hepatic triglyceride synthesis. FFA influx and neosynthesis outweigh FFA oxidation 
and triglyceride secretion, resulting in the net effect of hepatic fat accumulation. This 
can explain a key role of insulin resistance in the development of hepatic steatosis 
and, potentially, steatohepatitis (Figure 2) [43-48]. 
The resulting accumulation of fat within the hepatocytes has several effects. FFAs 
impair insulin signalling and cause hepatic insulin resistance via mechanisms 
involving activation of PKC-3, JNK, I-kB kinase β (IKK-β) and NFkB [49,50]. Hepatic 
insulin resistance then increases mitochondrial fatty acids oxidation. Besides, FFAs 
and their metabolites are ligands for peroxisomal proliferators-activated receptor-α 
(PPAR-α), the transcription factor that regulates the expression of different genes 
encoding enzymes involved in mitochondrial, peroxisomal and microsomal fatty acids 
oxidation. Finally, it appears that both consequences of fat accumulation within the 
liver (fat-induced hepatic insulin resistance and up-regulation of PPAR-α-regulated 
genes) result in increased FFA oxidation. Mitochondrial and peroxisomal fatty acids 
oxidation are both capable of producing hepatotoxic free oxygen radicals that 
contribute to the development of oxidative stress [51-54]. Considering all this data, it 
appears that insulin resistance could in fact deliver both ‘hits’ in the pathogenesis of 
NASH. Considerable mitochondrial structural abnormalities were found in patients 
with NASH but not in those with simple hepatic steatosis [46, 55-58]. It has also been 
found that several genes important for mitochondrial function were underexpressed 
in NASH patients [59]. Aforementioned oxidative stress and subsequent lipid 
peroxidation are the factors supposed to alter both mitochondrial DNA and 
mitochondrial oxidative phosphorylation, leading to mitochondrial structural 
abnormalities and ATP depletion [60, 61]. However, it is also possible that this 
mitochondrial abnormalities are the preexisting condition that enables excessive free 
oxygen radical species production in the setting of enhanced FFA beta-oxidation [46]. 
This would mean that, in the absence of preexisting mitochondrial defects, insulin 
resistance will lead only to the development of simple hepatic steatosis.  
Many studies demonstrated that oxidative stress is a prominent feature of NASH 
[62-64]. Apart from hepatocytes, ROS production and oxidative stress can in obese 
patients also originate in adipose tissue (both in adipocytes and in macrophages 
infiltrating adipose tissue) [65,66]. Inflammatory cells within the liver represent the 
third potential source of ROS and oxidative stress, especially in the setting of already 
developped steatohepatitis.  
Hepatocyte reactive oxygen species accumulation (oxidative stress) could, at least 
to some extent, be responsible for further progression from steatosis to 
steatohepatitis and fibrosis. This could occur by three main mechanisms: lipid 
peroxidation, cytokine induction and Fas ligand induction. ROS-triggered lipid 
peroxidation of plasma or mitochondrial membranes causes cell necrosis or induces 
apoptosis. Lipid peroxidation also initiates release of malondialdehyde (MDA) and 4-
hydroxynonenal (HNE) that can bind to hepatocyte proteins forming neoantigens and 
initiating a potentially harmful immune response, cross-link cytokeratins to form 
Mallory hyaline, activate hepatic stellate cells promoting collagen synthesis and 
stimulate neutrophil chemotaxis [62, 67]. ROS also increases expression of Fas-ligand 
on hepatocytes that interacts with normally expressed membrane receptor Fas on 
the adjacent hepatocytes causing apoptotic cell death [68]. ROS may also initiate the 
activation of the transcription factor NF-kB which leads to the increased production of 
proinflammatory cytokines (TNF-α, TGF-β, IL-6, IL-8) [69].  
Furthermore there are convincing data that inflammatory cytokines (TNF-α, 
IL-6 and IL-1b) also play an important role in the pathogenesis of NAFLD [70]. They 
may cause systemic and hepatic insulin resistance [71]. They also cause hepatocyte 
injury and apoptosis, neutrophil chemotaxis, and hepatic stellate cell activation [72-74]. 
Crespo et al. have found that obese patients with NASH compared to those without it 
have significantly increased liver expression of TNF-α and its receptor p55, as well as 
increased expression of TNF-α in adipose tissue [75]. This increased expression 
correlated with the degree of liver fibrosis. FFAs accumulated in hepatocytes 
stimulate NF-κB-dependent inflammatory cytokine expression (TNF-α, IL-6, IL-1b) [76, 
77]. Kupffer cells are, as the liver specific macrophages, also a potent source of 
proinflammatory cytokines. Activating stimulus could be hepatocyte-derived 
cytokines, clearance of oxidated lipid deposits via scavenger receptors [70], or gut-
derived endotoxins in patients with small intestinal bacterial overgrowth [78]. Finally, 
adipose tissue is in obese people infiltrated by macrophages [65], making it another 
possible source of proinflammatory cytokines [75, 79]. It appears that cytokines 
produced by adipose tissue macrophages (particularly TNF-α) could mediate systemic 
and hepatic insulin resistance [71], as well as cause a reduction in the secretion of the 
protective adipocytokine adiponectin [80]. 
Adipocytokines are peptides produced by visceral adipose tissue. Among 
them, adiponectin and leptin are directly involved in different metabolic and 
inflammatory pathways and could be particularly important in the pathogenesis of 
NAFLD. Adiponectin appears to have a pivotal role in improving fatty acid oxidation 
and decreasing fatty acid synthesis [81]. Liver and muscle cells have adiponectin 
receptors. Stimulation of adiponectin receptors in the liver leads to the activation of 
PPAR-α and AMP-activated protein kinase (AMPK) [82-84]. Consequently, adiponectin 
increases fatty acid β-oxidation and thereby decreases hepatic triglyceride content 
and hepatic insulin resistance. Adiponectin also has a direct anti-inflammatory effect, 
suppressing TNF-α production in the liver [80, 81]. Recent studies showed reduced 
serum levels of adiponectin and reduced hepatic expression of its receptor in patients 
with NASH compared to those with simple steatosis [85, 86]. It seems that increased 
production of TNF-α and the generation of ROS are the ones responsible for the 
reduction in adiponectin secretion [66, 80]. This again implicates that TNF-α and ROS-
mediated suppression of adiponectin may play an important role in the pathogenesis 
of progressive NAFLD. A study in obese leptin-deficient mice demonstrated significant 
improvements in hepatic steatosis, hepatomegaly, and aminotransferase levels 
following administration of adiponectin [81].  
Leptin is another peptide produced in adipose tissue that may have an important role 
in the development of insulin resistance. Leptin inactivates insulin receptor substrate 
(dephosphorylation of insulin-receptor substrate 1) inducing peripheral and hepatic 
insulin resistance [87]. Blood leptin levels correlate with the degree of fibrosis in 
patients with chronic hepatitis C [88], however Angulo et al. have found no correlation 
between leptin levels and stage of liver fibrosis in a study of 88 patients with NAFLD 
[89]. Cohen et al. have found that leptin, at the levels comparable with those present 
in obese individuals, induces hepatic insuline resistance by dephosphorylation of 
insulin-receptor substrate 1 [87].  
In the end, hepatocyte injury and associated inflammation will lead to the activation 
of hepatic stellate cells and synthesis of extracellular matrix proteins with liver 
fibrosis as the final consequence. In addition, apoptotic cell death is also of great 
importance in hepatic fibrogenesis [68]. It leads to stellate cell activation by the 
means of ingestion of apoptosing hepatocytes by Kupffer cells and subsequent 
release of TGF-β [90, 91]. There are several more mediators possibly involved in the 
pathogenesis of liver fibrosis in NAFLD. The adipocytokine leptin may play a role in 
fibrogenesis [89, 92]. The reduced production of adiponectin associated with obesity 
may also contribute to the development of liver fibrosis [93]. Angiotensin II, which is 
also secreted by adipose tissue and is raised in the serum of obese patients, 
stimulates hepatic stellate cells and thus has profibrogenic effect [94]. Finally, 
hyperglycaemia and hyperinsulinaemia associated with insulin resistance are also 
suggested to be the key-factors in the progression of fibrosis through the up-
regulation of synthesis connective tissue growth factor by stellate cells [95].  
Despite all of the recent advances in understanding the pathogenesis of 
NAFLD, the reason why only a minority of patients with classical risk factors for 
NAFLD develop more than simple steatosis still remains largely unclear. (Figure 2.) 
 
WHAT TO EXPECT FOR THE PATIENT? - NATURAL HISTORY AND CLINICAL 
COURSE OF NAFLD 
 
In spite of the increasing interest and significant progress in understanding of 
NAFLD, its natural history still hasn't been clearly defined. The reason for this is 
mostly the lack of large prospective histologic follow-up studies. However, some 
concepts are clear: NASH progresses to cirrhosis less frequently than alcoholic 
steatohepatitis, with significantly better long-term survival of NASH patients [96, 97]. 
Nevertheless, in a population-based study that used data from a large long-term 
epidemiology project, patients with NAFLD had a slightly higher mortality than the 
general population [98]. Liver-related death was the third most common cause of 
mortality in those patients, compared to the thirteenth place of liver-related death in 
the general population [98]. Another retrospective study of 132 patients found that 
poor outcomes (cirrhosis and liver-related mortality) occurred in 22 percent of 
patients in whom initial biopsies showed ballooning degeneration and Mallory hyaline 
or fibrosis, compared to 4 percent in patients with steatosis alone [97].  
There has been a lot of speculation about the rate of progression of disease.  Initial 
studies with paired biopsies showed histologic progression in 30 to 50% of NASH 
patients, but they had limited conclusions due to small patient numbers [12, 15, 99, 100]. 
The largest reported series of NAFLD patients with sequential liver biopsies published 
in 2005 included 103 patients with a mean interval of 3.2 years between biopsies 
[101]. Fibrosis stage progressed in 37%, remained stable in 34% and regressed in 
29% of patients. Diabetes, low initial fibrosis stage and higher body mass index were 
associated with higher rate of fibrosis progression.  
Another study of 22 patients with a median 4.3-year interval between biopsies also 
found progression of fibrosis in about a third of patients, with obesity and higher 
body mass index being the only associated factors [102].  
According to these results it became obvious that NAFLD, and especially NASH, is not 
a completely benign condition as it was initially believed. Now it is clear that it may 
lead to end-stage liver disease, and small number of patients with NAFLD may 
eventually end up with liver transplantation. Interestingly, steatosis and 
steatohepatitis recurrence after liver transplantation has been described [103]. 
Furthermore, several studies suggested that hepatocellular carcinoma (HCC) might 
also be among possible NAFLD outcomes [104-106]. Further studies are required before 
the risk of HCC in NAFLD can be more precisely defined. 
 
HOW TO DIAGNOSE? - THE ROLE OF THE LIVER BIOPSY 
Most patients with NAFLD come to medical attention due to an accidental finding of 
elevated liver function tests. Although aminotransferase levels are elevated in the 
majority of patients, normal values don’t exclude the presence of necroinflammatory 
changes or fibrosis. That was best illustrated in a study of 51 subjects with normal 
ALT levels where 12 had bridging fibrosis and 6 had cirrhosis [107].  
In the longitudinal histologic study of 103 patients aminotransferase improvement 
correlated with improvement in activity grade, but change in aminotransferase levels 
didn't correlate with a change in fibrosis stage. Interestingly, aminotransferase levels 
decreased significantly between biopsies both in patients with progressive fibrosis as 
well as in those without it [101]. 
Imaging methods are of little value in diagnostic evaluation of NAFLD. Finding of 
hyperechoic liver on ultrasonography is frequent in NAFLD, but it is neither sensitive 
nor specific enough. Moreover, all of the three most commonly used imaging 
methods (US, CT, MRI) have been shown to be incapable of differentiating between 
NASH and other forms of NAFLD [108]. 
The role of the liver biopsy in NAFLD has been widely discussed, and correlation 
between histologic findings and clinical features or disease prognosis extensively 
studied. Liver biopsy is currently the only way to confirm the NAFLD diagnosis and 
distinguish between fatty liver alone and NASH. It also permits determination of 
disease severity and possibly gives insight into prognosis. Nevertheless, no guidelines 
or firm recommendations can yet be made as for when and in whom is liver biopsy 
necessary.   
Another problem with liver biopsy is that it has several significant limitations. First, 
the quality of liver biopsy specimens is variable. Furthermore, studies have shown 
significant inter- and intra-observer variability in biopsy specimen interpretation [109, 
110]. Additionally, it has long been known that affection of liver parenchyma in various 
chronic liver diseases is not homogenous, and biopsy is therefore subject to sampling 
variability [111]. This has also been proven for NASH in a study in which two liver 
biopsies were performed in 51 patients with NAFLD [112]. None of the histological 
features displayed high agreement between two samples from the same patient. Six 
of 17 patients (35%) with bridging fibrosis on one sample had only mild or no 
fibrosis on the other and therefore could have been understaged with only one 
biopsy. The negative predictive value of a single biopsy for the diagnosis of NASH 
was at best 0.74, and discordance of one or more stages was 41%.  
In order to overcome some of the frequently present difficulties in liver biopsy 
interpretation, Matteoni et al. divided NAFLD into four categories or types, based on 
the presence of steatosis, lobular inflammation, hepatocyte ballooning and Mallory 
bodies/fibrosis [97]. Types 3 and 4 were associated with worse clinical outcomes. 
The first histological scoring system for NASH was proposed by Brunt and al. and it 
was designed based on a model used in other chronic liver diseases and included 3 
qualitatively assessed grades of necroinflammatory activity (based on degree of 
steatosis, balooning and inflammation) and 4 stages of fibrosis [113]. However, it 
didn’t include the whole spectrum of NAFLD and it couldn’t be used in assessment of 
response to therapy. Therefore, another scoring system has been developed, which 
specifically includes only features of active injury that are potentially reversible in the 
short term [110]. The score, named NAS (NAFLD Activity Score), is the unweighted 
sum of the scores for steatosis (0-3), lobular inflammation (0-3), and ballooning (0-
2), while fibrosis was not included. The primary purpose of NAS is to assess overall 
histological change; it wasn't designed to replace the pathologist's determination of 
steatohepatitis, nor to represent an absolute severity scale. 
In spite of all the efforts, there is still no international consensus regarding the 
histopathological criteria that would firmly define non-alcoholic steatohepatitis and 
differentiate between NAFLD entities. Therefore, a large amount of confusion 
between pathologists and clinicans is still present. As an illustration, in NAS 
development study interrater agreement on the diagnosis of steatohepatitis was 
0.61, and only 68% of liver biopsies with steatosis, ballooning and lobular 
inflammation all present were diagnosed as NASH [110].  
Several clinical and biochemical risk factors for progressive disease have been 
identified, as they could potentially facilitate patient selection for liver biopsy. In one 
study, age over 45, obesity, diabetes mellitus, and aspartate transaminase/alanine 
transaminase (AST/ALT) ratio greater than 1 were significant predictors of severe 
liver fibrosis [16]. In another study, age over 50 years, BMI over 28, triglycerides over 
1.7 mmol/L and alanine aminotransferase more than two times normal were 
independently associated with septal fibrosis [114]. 
In conclusion, for the time being, the decision to perform liver biopsy remains highly 
individual, as well as the interpretation of the histopathologic finding.   
 
AVAILABLE TREATMENT OPTIONS 
NAFLD as the hepatic manifestation of metabolic syndrome is emerging as the most 
common clinically important form of liver disease in obese patients [9,14]. Obesity, 
along with insulin resistance, type 2 diabetes and dyslipidemia, is a central risk factor 
for NAFLD. Lifestyle modifications, which should include long-term weight 
management through induction of negative calorie balance (primarily reducing in 
dietary carbohydrate and saturated fat intake), regular physical exercise with 
maintenance of weight loss and cognitive-behavior programs are the mainstays of 
the successful therapy of metabolic syndrome. Specific diet and exercise guidelines 
for NAFLD patients have not been established, but several types of diets have been 
proposed for treatment of obesity by different medical and commercial sources [115-
117]. Although the published results of several studies in NAFLD population are mostly 
insufficient due to their small sample size, they have reported that short term weight 
loss with concomitant exercise leads to improvement in liver biochemical tests and to 
resolution of hepatic steatosis [118-120]. Moderate weight loss with incorporated 
regular physical activity is advocated in contrast to rapid weigh loss, which could 
aggravate the underlying liver disease. A recent study showed that weight reduction 
of 5 or more percent accompanied by regular exercise (at least twice a week) for one 
year were associated with improvement and normalization in ALT levels [121]. Keeping 
this weight (<5% gain) for two consecutive years was associated with maintaining 
normal ALT levels. Another recent study reported that intense dietary intervention 
can achieve a reduction in mean waist circumference, insulin resistance, levels of 
fasting glucose, triglycerides and liver function tests, as well as an improvement in 
liver histology in patients with NASH [122].  
Pharmacological treatment should be initiated only when there is no change in the 
course of disease after adequate lifestyle changes have been undertaken. The 
problem is that appropriate diet and physical activity in addition to behavioral 
modifications are not always successful, particularly in very obese NAFLD patients. A 
pilot study which included ten obese NASH patients treated with weight-loss drug 
orlistat (inhibitor of pancreatic and gastric lipase) for 6 months showed that 10% or 
greater consequent body weight reduction leads to improvement in aminotransferase 
levels, liver steatosis and fibrosis [123].  
Bariatric surgery is considered to be the best therapeutic modality in NAFLD patients 
with severe obesity or with concomitant obesity-associated morbidities, like sleep 
apnea syndrome [124]. There are different surgical approaches to morbidly obese 
patients: malabsorptive procedures, such as jejuno-ileal bypass and biliopancreatic 
diversions, and restricitive procedures, which include gastric bypass and gastroplasty 
(gastric banding). Jejuno-ileal bypass, as the more 'classical' procedure, has been 
virtually replaced by 'newer' procedures such as proximal gastric bypass and 
biliopancretic diversion, mostly due to the high frequency of postoperative 
complications [125, 126]. Those included progression of liver disease, although, 
occasional cases of NASH progression and subacute liver failure have also been 
reported with 'newer' methods. Few recent trials reported that moderate or even 
massive weight loss with consequent mild to moderate malnutrition after 
gastroplasty in severe obese NASH patients resulted in improvement in diabetes 
mellitus, liver function tests and liver histology (inflammation and fibrosis) [124,127-130]. 
Similar results were reported after gastric bypass surgery [20]. Even though these 
promising results give a new perspective on treatment of severely obese NAFLD 
patients, the decision to perform surgery should still be individual.        
The role of smoking and minimal to moderate alcohol intake in pathogenesis and 
potential progression of NAFLD has not been widely investigated, therefore specific 
recommendations regarding those factors cannot be made.  
Lipid-lowering agents. One year pilot study which evaluated a lipid-lowering drug 
clofibrate in the treatment of  16 patients with hypertriglyceridemia and NASH 
revealed no significant changes in levels of aminotransferases or liver histology [132]. 
A controlled trial of a 4-week treatment in 46 patients with NASH using gemfibrozil 
600 mg/day resulted in a significant improvement in liver tests, although study didn’t 
include liver biopsies [133]. A total of 56 patients with NAFLD/NASH and 
hyperlipidemia was investigated in three separate studies and received 3-hydroxy-3-
metylglutaryl coenzyme A (HMG CoA) reductase inhibitor atorvastatin (10-80 
mg/day) for 6-12 months, which lead to significant improvement or normalization in 
serum aminotransferase and lipids/cholesterol levels, as well as in the degree of 
inflammation, ballooning and Mallory bodies on liver histology [134-136]. A small study 
using another HMG CoA reductase inhibitor pravastatin included 5 patients with 
biopsy proven NASH [137]. After 6 months of pravastatin treatment cholesterol levels 
were reduced, with normalization of liver function tests but without improvement in 
the fibrosis score.   
Metformin. Metformin is an insulin-sensitizing agent that reportedly reversed 
hepatomegaly, steatosis and liver tests abnormalities in an animal model of fatty liver 
[138]. First pilot study which investigated metformin treatment (500 mg three times 
daily) in patients with NASH suggested association of usage of this agent with 
improvement in liver tests and index of insulin sensitivity, as well as decrease in 
hepatic volume [139]. A possible benefit of metformin in induction of normalization of 
liver tests and loss of body weight was reported after 6 months of therapy in a 
preliminary report of an open-label study of 15 patients [140]. However, consequent 
results after 1 year of treatment showed no effect on aminostransferase levels, liver 
histology, or insulin sensitivity [141]. Another randomized controlled study in patients 
with NAFLD reported that addition of metformin to a lipid and calorie-restricted diet 
vs. diet alone for 6 months lead to improvement in mean serum aminotransferase 
levels and insulin resistance. On the other hand, no statistically significant change in 
the severity of liver inflammation or fibrosis at the end of the treatment period was 
reported [142]. Higher rates of aminotransferase normalization and improvement in 
liver histology and insulin sensitivity were associated with metformin treatment in 
comparison to vitamin E treatment or weight loss in an open-label randomized study 
of 110 non-diabetic patients [143].  
Thiazolidinediones. Thiazolidinediones (pioglitazone, rosiglitazone), peroxisome 
proliferator-activated receptor (PPAR) gamma ligands, are insulin-sensitizing drugs 
involved in glucose and lipid metabolism with suggested anti-inflammatory and anti-
fibrotic properties [144]. They are a new class of antidiabetic agents investigated 
recently as a potential treatment modality for patients with NAFLD/NASH. PPAR-
gamma agonist pioglitazone prevents the activation of hepatic stellate cells in vitro, 
and improves hepatic steatosis and prevents liver fibrosis in vivo  [145]. In another 
study with animals 1 week treatment with pioglitazone inhibited hepatic fat 
accumulation and decreased levels of TNF-alpha, while 4 week treatment lead to 
improvement in hepatic fibrosis with a decrease in the expression of procollagen, 
alpha-smooth muscle actin, and TGF-β1 [146]
studies, 48 weeks of pioglitazone treatment (30 mg daily) of nondiabetic patients 
with biopsy-proven NASH improved the degree of insulin sensitivity with 
normalization of aminotransferase levels and histological improvement in hepatic 
steatosis, cellular injury, parenchymal inflammation, Mallory bodies, and fibrosis [147]. 
MRI confirmed a marked decrease in liver fat and liver volume, but interestingly, 
increase in body weight and total body fat was observed. In another controlled study 
combination treatment with pioglitazone (30 mg daily) and vitamin E (400 IU daily) 
normalized aminotransferase levels, but the effect was also seen in the control group 
treated with vitamin E alone [148]. However, only combination therapy induced a 
significant effect on histological findings (decrease in steatosis, hepatocyte 
ballooning, Mallory's bodies and pericellular fibrosis), with improvement in metabolic 
disturbances (increase in metabolic clearance of glucose and a decrease in fasting 
free fatty acid and insulin). A recent study proposed that improvements seen on liver 
histology after pioglitazone therapy may be the effect of change in adiponectin levels 
[149]. In another study of rosiglitazone in 25 NASH patients of whom half had diabetes 
or impaired glucose tolerance, 1-year therapy was associated with improvement in 
liver function tests, insulin sensitivity and degree of fibrosis [150]. Opposite to this 
promising results, the latest meta-analysis of 42 trials with rosiglitazone found that 
the drug was associated with significant increase in the risk of myocardial infarction 
[151]. Considering all this, recommendations about use of thiazolidinediones in NAFLD 
treatment can not be yet established.  
Losartan. A role for angiotensin II in pathogenesis of hepatic stellate cell activation, 
hepatic inflammation and  fibrogenesis has been postulated [152-156]. Given the 
potential therapeutic effects of angiotensin II receptor antagonists, studies with 
losartan were performed in patients with NASH and arterial hypertension [157-159]. 
Reduction in levels of blood markers of hepatic fibrosis, transforming growth factor-
β1 (TGF-β1) and ferritin concentration was reported, with improvement in serum 
aminotransferase levels. Reduction of hepatic necroinflammation, fibrosis and iron 
hepatocyte deposition was detected in the majority of liver biopsy specimens after 48 
weeks of treatment. Results suggest anti-fibrotic effect of losartan through inhibitory 
effect on hepatic stellate cell activation. These promising initial results justify further 
studies of angiotensin II receptor antagonists in treatment of NAFLD patients. 
Antioxidants. Oxidative stress, along with the insulin resistance, plays one of the 
essential roles in NAFLD pathogenesis. Therefore, treatment with different 
antioxidants (vitamin E, vitamin C, betaine, iron depletion) has been studied in this 
group of patients. A study with vitamin E administration (300 mg/day during 1 year) 
confirmed improvement in liver tests with reduction of plasma levels of TGF β1 but 
revealed no change in degree of steatosis, fibrosis and inflammation on follow-up 
liver biopsy [160]. A placebo-controlled trial of a combination of vitamin E (1000 
IU/daily) and vitamin C (1000 mg/day) during 6 months showed no statistically 
significant difference between vitamin and placebo groups in liver enzyme levels, 
degree of steatosis and inflammatory activity, or fibrosis score, although an 
improvement in fibrosis was noted in the vitamin group [161]. Given the suggested 
protective effect of betaine against steatosis in rats (through increase of S-
adenosylmethionine levels), a pilot study was performed in 8 patients with NASH 
[162]. After one year treatment with betaine (20 mg daily), a significant improvement 
or normalization in serum aminotransferase levels and liver histology was noted. 
Another placebo-controlled study included 191 patients with NAFLD treated for 8 
weeks with combination of betaine glucuronate (300 mg/day), diethanolamine and 
nicotinamide ascorbate [163]. Significant improvement was noted in liver tests and 
degree of steatosis (evaluated by ultrasonography) in the treated group. Further 
controlled trials are needed for confirmation of these promising results. It has been 
hypothesized that iron induces oxidative stress by catalyzing production of ROS 
(reactive oxygen species) and increased hepatic iron deposition could be a part of 
the pathogenesis of NAFLD [164]. In a few pilot studies in NASH patients, quantitative 
phlebotomies were performed with induction of iron depletion and reduction in 
serum ferritin levels [165-167]. Results of these studies suggest that iron reduction 
therapy by phlebotomy can lead to improvement in aminotransferase levels; 
unfortunately, follow-up liver biopsies were not performed. 
Ursodeoxycholic acid. Ursodeoxycholic acid (UDCA) could potentially act as a 
hepatoprotective agent by minimizing toxicity of hydrophobic bile acids and leading 
to a decrease in oxidative stress and hepatocyte injury. Initial small pilot-studies 
evaluated therapeutic effect of UDCA alone or in combination with low-fat diet or 
lipid-lowering agents in patients with NASH [132, 135, 168-170]. Results suggested 
potential benefit of UDCA treatment with reported normalization/improvement in liver 
function tests, degree of hepatic steatosis and serum markers of fibrosis. However, 
consequent larger, randomized double-blinded placebo-controlled trial found no 
detectable benefit of UDCA treatment: similar degree of improvement in biochemistry 
and histology was detected in both study groups [171]. Given the lack of effectiveness 
of UDCA alone as a therapeutic option in NASH, one recent study considered 
combination of UDCA with vitamin E. Significantly diminished levels of serum 
aminotransferases were observed, with improvement in histological activity index, 
mostly as a result of regression of steatosis [172].  
 
CONCLUSION 
Non-alcoholic fatty liver disease is currently the object of significant scientific and 
clinical interest, and is to remain so in the following years. Larger studies with firm 
inferences are rather scarce, and their small number reflects the difficulties in 
setting-up and performing clinical trials in NAFLD. Among the most important 
obstacles that researchers are confronted with are slowly progressive nature of the 
disease requiring long-term follow-up, variability in liver biopsy specimens and their 
interpretation, various associated conditions and multiple medication use that are 
common in these patients. Although clinicians dispose in theory with a wide array of 
possible therapies, few have been shown to have consistent effects and can 
therefore be firmly recommended in treatment of NAFLD. 
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 Figure 1. Lipid metabolism within the hepatocytes. 
 
 
Liver lipid content is determined by the equilibrium of several processes: import of 
free fatty acids (FFAs) from the adipose tissue, de novo FFA synthesis in 
hepatocytes, beta-oxidation of FFAs, esterification of FFAs into triglycerides and 
export of triglycerides as very low density lipoproteins (VLDL). Hepatic steatosisis is a 
consequence of imbalance in those processes in favour of excessive triglyceride (TG) 
accumulation. (abbreviations: FFA - free fatty acids; TG – triglycerides; VLDL - very 
low density lipoproteins; Apo B - apolipoprotein B) 
 
 
 
Figure 2. Effects of insulin resistance on lipid metabolism. 
 
 
Insulin resistance and resulting hyperinsulinemia lead to hepatocyte lipid 
accumulation in the liver by several mechanisms. In adipose tissue, insulin resistance 
enhances triglyceride (TG) lipolysis and inhibits esterification of free fatty acids 
(FFAs). The result are increased circulating levels of FFAs, which are then taken up 
by the liver. Additionally, in hepatocytes hyperinsulinemia increases the ‘de novo’ 
synthesis of fatty acids and inhibits their beta oxidation. The consequence is 
accumulation of FFAs within hepatocytes. Hepatic TG synthesis is driven by the 
increased hepatocyte FFA content and favoured by insulin-mediated upregulation of 
lipogenic enzymes, such as peroxisome proliferator-activated receptor gamma 
(PPAR-γ) and sterol regulatory element binding protein 1 (SREBP-1). Meanwhile, 
reduced very-low-density lipoprotein (VLDL) production and TG export may be 
impaired by decreased synthesis of apolipoprotein B (apo B) or reduced binding of 
TG to apo B by microsomal triglyceride transfer protein (MTP). The resulting 
accumulation of fat within the hepatocytes initiates further damage causing hepatic 
insulin resistance and reactive oxygen species production. (abbrevations: ↑ - 
icreased; ↓ - inhibits; FFA - free fatty acid; TG – triglyceride; VLDL - very low density 
lipoprotein; Apo B apolipoprotein B) 
 ↑ - icreased; ↓ - inhibits; FFA - free fatty acid; TG – triglyceride; VLDL - very low 
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